Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Replacement Therapy in CRPC
NCT00577980Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of testosterone enanthate in castration-resistant prostate cancer (CRPC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2007; status: withdrawn.
02
Drugs
testosterone enanthate
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00577980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577980.